The prevalence of pancreatic cancer is expected to increase, presenting a major economic and health care burden for the 21st century. The majority of pancreatic cancer patients are diagnosed at advanced or late stage. Until now, little is known about virotherapy immune-resistance as well as genomic variation that dictate response to oncolytic viruses. Therefore, my research theme is to define a novel genomic biomarker to predict the response of pancreatic cancer patients to available treatment as well as ongoing clinical trials using OVs. We hypothesis that not only the genomic variation but also the cellular compartment variation could be related to the resistance of OV therapy. Therefore, the outcome of this research will be linked with cellular compartment of pancreatic cancer to facilitate the discovery of precisely predictive biomarkers for OV therapy that could be tested in clinical trials which could reduce medical and nursing care expenses and decreases in the labor pool.